The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort
- 827 Downloads
The objective of this study was to evaluate the efficacy and safety of fidaxomicin in the real-life clinical setting. This was a retrospective cohort of patients with Clostridium difficile infection (CDI) treated with fidaxomicin in 20 Spanish hospitals between July 2013 and July 2014. Clinical cure, 30-day recurrence, 30-day mortality, sustained cure, and factors associated with the failure to achieve sustained cure were analyzed. Of the 72 patients in the cohort 41 (56.9 %) had a fatal underlying disease. There were 44 (61.1 %) recurrent episodes and 26 cases (36.1 %) with a history of multiple recurrences. Most episodes were severe (26, 36 %) or severe-complicated (14, 19.4 %). Clinical cure rate was 90.3 %, recurrence rate was 16.7 % and three patients (4.2 %) died during the follow-up period. Sustained cure was achieved in 52 cases (72.2 %). Adverse events were reported in five cases (6.9 %). Factors associated with the lack of sustained cure were cardiovascular comorbidity (OR 11.4; 95 %CI 1.9–67.8), acute kidney failure (OR 7.4; 95 %CI 1.3–43.1), concomitant systemic antibiotic treatment (OR 6.2; 95 %CI 1.1–36.8), and C-reactive protein value at diagnosis (OR 1.2 for each 1 mg/dl increase; 95 %CI 1.03–1.3). Fidaxomicin is an effective and well tolerable treatment for severe CDI and for cases with elevated recurrence risk.
KeywordsClostridium Difficile Infection Clinical Cure Tigecycline Fidaxomicin Clostridium Difficile Infection Recurrence
The authors would like to express their gratitude for the data collection to the following people: María Soledad Azcona, Unit of Internal Medicine, Hospital Santa Marina, Bilbao, Spain. Cristina Badía, Unit of Nosocomial Infections, Hospital Universitari Mútua Terrassa, Terrassa (Barcelona), Spain. Juan Miguel Bergua Burgués, Department of Hematology Department. Hospital San Pedro de Alcántara, Cáceres, Spain. María Bodi, Department of Critical Surgical Care, Hospital Joan XXIII, Tarragona, Spain. María Teresa Bravo Fernández, Department of Gastroenterology, Hospital de Basurto, Bilbao, Spain. Elena Chamorro, Unit of Internal Medicine, Hospital Verge de la Cinta, Tortosa, Spain. Beatriz Díaz Pollán, Unit of Infectious Diseases and Clinical Microbiology, Department of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain. Elena Espejo, Unit of Infectious Diseases, Department of Internal Medicine, Consorci Sanitari de Terrassa, Terrassa, Spain. Alicia Hernández Torre, Department of Infectious Diseases, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain. Samantha Elizabeth de Jesús, Department of Infectious Diseases, Hospital Universitario Virgen de las Nieves, Granada, Spain. Belén Loeches Yagüe, Unit of Infectious Diseases and Clinical Microbiology, Department of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain. Thais López, Department of Infectious Diseases, Hospital Vall d’Hebron, Barcelona, Spain. Helena Monzón. Unit of Internal Medicine, Hospital San Joan de Deu, Martorell, Spain. Juan Francisco Pascual Gázquez, Department of Paediatric Haematology and Oncology. Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain. Alicia Rico Nieto, Unit of Infectious Diseases and Clinical Microbiology, Department of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain. Andrés Sánchez Salinas, Department of Hematology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain. Julio Valle, Department of Gastroenterology, Hospital Virgen de la Salud, Toledo, Spain.
Compliance with ethical standards
Conflict of interest
C. F. received support to attend scientific meetings and congresses from Glaxo-Smith-Klein, Pfizer, Astellas and Gilead. E. M. R. received honoraria from Astellas for scientific presentations. M. S. gave scientific presentations at meetings organized by Pfizer, Astellas, MSD, Novartis and Gilead, and received grants for research projects and clinical trials from Astellas and MSD. V. D. B. received lecture fees, travel support for attending meetings and fees for advisory boards from Novartis, Astellas, Merck and Pfizer. J. M. gave scientific presentations at meetings organized by Novartis, Pfizer, MSD, Astellas, and Gilead. All other authors had no competing interests to declare.
This work was an Investigator Sponsored Research supported by Astellas Pharma.
- 2.Cornely O, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K et al (2012) Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet 12:281–289. doi: 10.1016/S0140-6736(11)61514-6.WEB-ONLY CrossRefPubMedGoogle Scholar
- 4.Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IAO (2014) Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 69:2892–2900. doi: 10.1093/jac/dku261 CrossRefPubMedGoogle Scholar
- 7.Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M et al (2012) Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile Infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 55:S132–S142. doi: 10.1093/cid/cis338 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Deshpande A, Hurless K, Cadnum JL, Chesnel L, Gao L, Chan L et al (2016) Effect of fidaxomicin versus vancomycin on susceptibility to intestinal colonization with vancomycin-resistant enterococci and Klebsiella pneumoniae in mice. Antimicrob Agents Chemother 60:3988–3993. doi: 10.1128/AAC.02904-15 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Snydman DR, McDermott LA, Jacobus NV, Thorpe C, Stone S, Jenkins SG et al (2015) U.S.-based national sentinel surveillance study for the epidemiology of clostridium difficile-associated diarrheal isolates and their susceptibility to fidaxomicin. Antimicrob Agents Chemother 59:6437–6443. doi: 10.1128/AAC.00845-15 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Trubiano JA, Cheng AC, Korman TM, Roder C, Campbell A, May MLA et al (2016) Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. Intern Med J 46:479–493. doi: 10.1111/imj.13027 CrossRefPubMedGoogle Scholar
- 23.Clutter DS, Dubrovskaya Y, Merl MY, Teperman L, Press R, Safdar A (2013) Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 57:4501–4505. doi: 10.1128/AAC.01120-13 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Goldenberg S, Brown S, Edwards L, Gnanarajah D, Howard P, Jenkins D et al (2016) The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis 35:251–259. doi: 10.1007/s10096-015-2538-z CrossRefPubMedGoogle Scholar
- 27.Charlson ME, Pompei P, Ales KL, MacKenzie R (1987) A new method of classifying prognostic in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383Google Scholar
- 29.Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC et al (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31:431–455. doi: 10.1086/651706 CrossRefPubMedGoogle Scholar
- 30.Miller MA, Louie T, Mullane K, Weiss K, Lentnek A, Golan Y et al (2013) Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis 13:148–154. doi: 10.1186/1471-2334-13-148 CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Hardt C, Berns T, Treder W, Dumoulin FL, Hardt C, Dumoulin FL (2008) Univariate and multivariate analysis of risk factors for severe clostridium difficile -associated diarrhoea: Importance of co-morbidity and serum C-reactive protein. World J Gastroenterol 14:4338–4341. doi: 10.3748/wjg.14.4338 CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A et al (2010) Health care – associated clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 50:194–201. doi: 10.1086/649213 CrossRefPubMedGoogle Scholar
- 48.Rea MC, Dobson A, O’Sullivan O, Crispie F, Fouhy F, Cotter PD et al (2011) Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci USA 108:4639–4644. doi: 10.1073/pnas.1001224107 CrossRefPubMedGoogle Scholar
- 49.Lewis BB, Buffie CG, Carter RA, Leiner I, Toussaint NC, Miller LC et al (2015) Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole. J Infect Dis 212:1656–1665. doi: 10.1093/infdis/jiv256 CrossRefPubMedPubMedCentralGoogle Scholar